The Global Hereditary Angioedema Market was valued at US$ 1,563.7 million in 2016 and is expected to witness a robust CAGR of 9.1% over the forecast period (2017 – 2025).
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE).
Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.
Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1292
North America dominates the hereditary angioedema market, owing to the higher number of drugs approved in the regions, presence of major manufacturers and the presence of various organizations serving HAE patients. In 2017, the U.S. Food and Drug Administration (FDA) approved Haegarda (C1-esterase inhibitor) manufactured by CSL Behring for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.
Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.